NCT04943991 - Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2024

Conditions

Fabry DiseaseFabry Disease, Cardiac VariantLysosomal Storage DiseasesHCM - Hypertrophic CardiomyopathyAnderson Fabry Disease

Interventions

DIAGNOSTIC_TEST

blood sampling (alpha-Galactosidase & LysoGb3)

"A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene"

Trial Locations (1)

97080

University Hospital Wuerzburg, Würzburg